<DOC>
	<DOCNO>NCT02429518</DOCNO>
	<brief_summary>This study Phase 4 , open-label , single group study least 40 adult patient undergoing miltefosine treatment mucocutaneous leishmaniasis ( CL ML ) assess 12-lead ECG prolongation correct QT interval</brief_summary>
	<brief_title>Dedicated QT Study Bolivian Patients Taking ImpavidoÂ® ( Miltefosine ) Mucocutaneous Leishmaniasis</brief_title>
	<detailed_description>This study Phase 4 , open-label , single group study least 40 adult patient undergoing miltefosine treatment mucocutaneous leishmaniasis assess digital 12-lead electrocardiogram ( ECG ) prolongation QTc interval . Potential subject diagnose mucocutaneous leishmaniasis planning undergo miltefosine treatment inform study undergo inform consent process . After obtain informed consent , subject screen 14-day period eligibility medical history include leishmaniasis diagnostics , physical examination , clinical laboratory measurement [ chemistry : alanine aminotransferase ( ALT ) , total bilirubin , creatinine , magnesium , calcium , potassium , sodium ; hematology : white blood cell ( WBC ) count , hemoglobin , platelet count ; pregnancy test female ] , ECG , medication use 28-day period start treatment . If eligible study , subject receive miltefosine 28 day target dose approximately 2.5 mg/kg/day . Screening enrollment study continue least 10 female 30 male complete study consider evaluable ( provide Day 28 ECGs PK sample complete least 25 28 day miltefosine treatment ) . Vital sign collect weekly treatment . Chemistries hematology repeat study Days 14 ( mid-treatment ) 28 ( end treatment ) . A pregnancy test ( applicable ) repeat Day 28 . ECGs ( 12-lead ) repeat Days 14 28 . Blood drawn pharmacokinetic ( PK ) assessments Days 14 28 within 15 minute final ECG . Adverse event ( AEs ) concomitant medication use collect treatment . If Day 28 , clinically significant abnormality observe ECG , repeat ECG PK blood draw perform Day 42 ( 2-weeks completing treatment ) . AEs concomitant medication use also collect subject come back Day 42 visit . Digital ECGs ( 12-lead ) collect triplicate time point period exceed 1 hour . During treatment , ECGs collect 4 hour dose ( approximate Tmax ) .</detailed_description>
	<mesh_term>Leishmaniasis</mesh_term>
	<mesh_term>Leishmaniasis , Mucocutaneous</mesh_term>
	<mesh_term>Miltefosine</mesh_term>
	<criteria>1 . Provide write informed consent . 2 . Be available complete study procedure 3 . Have diagnosis mucocutaneous leishmaniasis confirm microscopy stain smear lesion sample , culture lesion sample , polymerase chain reaction ( PCR ) lesion sample Montenegro skin test willing undergo treatment miltefosine 4 . Be male female 1855 year age 5 . Have ALT , total bilirubin , creatinine &lt; 1.5 upper ULN 6 . Have WBC count , hemoglobin , platelet count within 15 % WNL 7 . Be without clinically significant noncardiac medical disorder 8 . Have 12lead QTcF interval &lt; 450 msec , abnormal heart rate ( &lt; 40 &gt; 120 beats/min ) , PR interval ( from131 msec 197 msec male 120 196 msec female , QRS interval ( 78 msec 126 msec male 74 msec 114 msec female ) 9 . Have blood level ion might affect ECG WNL ( magnesium 1.82 mg/dL 2.41 mg/dL , calcium 8.5 mg/dL 10.5 mg/dL , potassium 3.5 mEq/L 10.5 mEq/L , sodium 135 mEq/L 148 mEq/L ) Have family history sudden cardiac death age 40 10 . Have personal history ischemic heart disease , congestive heart failure , palpitation , dizziness , syncope , cardiac arrhythmia 11 . If female , agree use effective method birth control start treatment 5 month complete treatment negative pregnancy test 1 . Be female breast feed 2 . Be female pregnant 3 . In past 28 day prior start miltefosine treatment receive drug treatment know significantly affect QTc interval 4 . Have positive serology Chagas disease</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>leishmaniasis</keyword>
	<keyword>miltefosine</keyword>
	<keyword>EKG</keyword>
</DOC>